New Thinking Needed On Reimbursement Of Cell And Gene Therapies
Executive Summary
One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.
You may also be interested in...
Italy Unveils New Payment Model For Novartis’s CAR-T Kymriah
The Italian authorities have agreed a new kind of reimbursement model for Novartis's CAR-T therapy Kymriah that involves payment in instalments depending on the patient’s response to treatment.
Novartis Strikes Kymriah Outcome-Based Deal With German Insurers
Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.
Another CAR-T First: Yescarta Wins Lymphoma Funding In England
Gilead has agreed a confidential deal with NHS England under which its pioneering CAR-T therapy Yescarta will be provided to adult lymphoma patients under the Cancer Drugs Fund. The funding decision gives Yescarta an edge in the lymphoma market over Kymriah, the other EU-authorized CAR-T treatment.